Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company, announced its participation in three upcoming investor conferences. These include the 42nd Annual Canaccord Genuity Growth Conference on August 11, 2022, the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, and the Baird 2022 Global Healthcare Conference on September 13, 2022. Allogene is focused on developing allogeneic CAR T products for cancer treatment. Webcasts of the presentations will be available on the company’s website.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in three upcoming investor conferences.
42nd Annual Canaccord Genuity Growth Conference
Thursday, August 11, 2022
Noon PT/3:00PM ET
H.C. Wainwright 24th Annual Global Investment Conference
Monday, September 12, 2022
Presentation time to be posted to www.allogene.com
Baird 2022 Global Healthcare Conference
Tuesday, September 13, 2022
12:45PM PT/3:45PM ET
Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for cancer and the potential benefits of AlloCAR T. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended March 31, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
FAQ
What is Allogene Therapeutics planning for investor conferences in August and September 2022?
Where can I find the webcasts for Allogene's investor presentations?
What are Allogene Therapeutics' focus areas in biotechnology?
When is the Baird 2022 Global Healthcare Conference?
What is the significance of Allogene's AlloCAR T products?
